4th October 2017 Diaprost announces a Research and Option Agreement with a leading Pharmaceutical company Share EmailTwitterFacebookGoogle +PinterestTumblrLinkedinVkontakte Diaprost have agreed terms for an exclusive Research and Option Agreement, inclusive of an upfront payment, research funding and potential development milestone payments for its h11B6 antibody for prostate cancer. Pressmeddelande Diaprost 4 okt 2017 Press release Diaprost oct 4 2017 2nd October 2018
